Breast Screening and Overdiagnosis: Reading the New Estimates Without Losing the Uncertainty
Overdiagnosis is not a false diagnosis, and five-year survival is not the effect of screening. Different numbers answer different questions.

In this article
The limits of the evidence first
Overdiagnosis cannot be confirmed immediately in an individual patient; it is usually estimated from long-term population data. The new analysis discussed here changes an estimation method and the interpretation of particular trial datasets. It does not establish one lower overdiagnosis rate for every screening program. Five-year survival in localized disease also cannot be read directly as the reduction in mortality attributable to screening.
I. The increasingly difficult question behind Pink October
Every October, pink appears on landmarks, social feeds, and health-check-center displays. Breast Cancer Awareness Month has a worthwhile purpose: early screening, diagnosis, and treatment can produce very high survival rates. For an individual, however, “Should I be screened?” has become harder to answer.
Why? On one side is the familiar idea that finding cancer sooner means living longer. On the other is a persistent concern: might screening find a cancer that would never have caused harm, leading to surgery or chemotherapy that was unnecessary? This is not an imaginary problem. It has a formal name: overdiagnosis. In September 2026, a reanalysis used different adjustments to estimate it, reaching results that differed from some earlier high estimates.
This article starts with that question. How many cancers found by breast screening would never have needed treatment? Where does the new evidence put the number? For women aged 40+, what should be set aside: fear, or a false sense of security?

Mount Bromo, photographed in Indonesia; the photograph is unrelated to screening evidence.
II. Background: why October, and why now?
Pink October, called Octobre Rose in French, is the global breast cancer awareness month, marked throughout October by the pink ribbon. On October 1, 2026, the Eiffel Tower, Empire State Building, Sydney Opera House, Tokyo Tower, and other landmarks glowed pink after dark to mark the launch of the 33rd Octobre Rose. The campaign reaches more than 70 countries, funds about 250 medical projects annually, and raises tens of millions of US dollars.
Why does it matter? Breast cancer has an important characteristic: earlier detection is associated with a greater chance of survival. Medical data consistently show that when disease is found at its earliest, localized stage within the breast, five-year relative survival can exceed 99%. This explains the continuing emphasis on early screening, diagnosis, and treatment. In France, breast cancer is women’s most common cancer and leading cause of cancer death; one in eight women develops it during her lifetime. The source also notes that around one in ten cases occurs below age 35 and approximately 1% in men: it has never been a disease only older women need to consider.
As incidence rises at younger ages, screening starts earlier. In 2024 the US Preventive Services Task Force (USPSTF) lowered its recommended starting age from 50 to 40, recommending mammography every two years between 40 and 74. The immediate reason was the increase in incidence among women aged 40–49 over the preceding decade. Behind Pink October’s message is an evidence framework being rewritten.
Lighting landmarks is not simply decoration. During October, health organizations offer subsidized mammograms, bring mobile screening to remote and underserved communities, and organize 5-km charity walks and survivor commemorations. They bring a subject often surrounded by shame and fear into public discussion, making “getting checked” an encouraged, supported action. For women over 40, its practical value is to bring an appropriate screening referral within reach and remind them that caring for their bodies is legitimate.
99%
Five-year relative survival for localized breast cancer; this alone cannot estimate the mortality reduction caused by screening
Age 40
The starting age for mammography recommended by USPSTF from 2024, previously 50
1/8
Estimated lifetime probability of invasive breast cancer in women

Lake Toba, North Sumatra, photographed in Indonesia; unrelated to screening evidence.
III. The evidence: a new calculation in the 2026 overdiagnosis debate
To understand women’s hesitation, first define overdiagnosis. Screening discovers a cancer or precancerous lesion, such as ductal carcinoma in situ (DCIS), that would never have become life-threatening or caused symptoms if it had remained undiscovered throughout life. Medicine cannot currently tell at detection whether a particular lesion will cause harm. Consequently, people often receive surgery, radiotherapy, and possibly endocrine therapy regardless of the lesion’s underlying danger. This is the basis of the concern about unnecessary treatment.
Much of the debate centers on ductal carcinoma in situ (DCIS). The source describes it as a “precancerous lesion”: abnormal cells remain inside the breast ducts, without crossing the basement membrane to invade surrounding tissue. Mammography is particularly good at finding DCIS, but some lesions might never progress to dangerous invasive cancer even if never discovered. Existing methods do not reliably separate those that will progress from those that will remain quiet, so surgery, radiotherapy, and sometimes endocrine therapy are widely used. How intensively DCIS should be treated remains one of the field’s most active debates, making overdiagnosis a real treatment decision rather than an abstract concept.
Estimates over the past two decades have varied enormously. An independent UK panel estimated around 19%, using diagnoses during the screening period among invited women as its denominator. The Canadian NBSS study gave a higher estimate; some observational studies suggested 30% or even 50%. Those figures underpin claims that screening could do more harm than good or should be avoided.
The September 14, 2026 JNCI analysis that may change the discussion
A team led by Njor at the University of Southern Denmark published a reanalysis in the Journal of the National Cancer Institute, using a common framework for eight classic randomized trials, including the New York Health Insurance Plan study, Swedish Two-County Trial, and Canadian National Breast Screening Study. Their key step was to use long-term data from Funen, Denmark, where organized screening began 17 years earlier, as a reference that restored often-neglected timing effects. Diagnoses rise when screening starts because cancers are brought forward in time, then should fall back. In addition, control groups in many trials underwent screening after the trials ended, potentially causing cancers that would have appeared later to be counted as excess diagnoses. After adjustment, the trial patterns were compatible with overdiagnosis below 5%, an order of magnitude below estimates approaching 50%.
Researcher Rebolj expressed this cautiously: interpreted in their full temporal context, the randomized-trial data are consistent with overdiagnosis below 5%, rather than near 50%. Njor said the benefits of early diagnosis and preventing premature death could now be considered to exceed the small risk of unnecessary treatment.
A frequently overlooked issue is how much of declining mortality should be attributed to screening itself. Researchers still disagree. Some analyses credit a substantial share of recent reductions to advances in treatment—targeted medicines, endocrine therapy, and improved chemotherapy—rather than screening alone. This does not remove screening’s value. It cautions against assigning every mortality improvement to screening and using that attribution to amplify or minimize overdiagnosis. Screening and treatment both matter.
This is nevertheless not an unconditional invitation to screen without concern. First, the study is a compatibility analysis, not a precise pooled estimate with a confidence interval. Second, it assumes Funen provides the appropriate counterfactual; another reference population might change the result. Third, reclassifying controls screened after trial exit accounts for an important part of the analysis and deserves independent scrutiny. Fourth, historical film mammography provides limited guidance on DCIS detection in today’s digital breast tomosynthesis (DBT) era. London breast surgeon Mokbel noted that the UK panel’s approximate 19% estimate and higher Canadian estimates underpin many current consent materials and decision aids. Honest counseling should acknowledge uncertainty in both directions: overestimating overdiagnosis can deter screening, while underestimating it erodes informed consent.
Translated into an ordinary decision: for an average-risk person especially anxious about unnecessary treatment, the new estimate below 5% supports screening’s benefits more strongly than older estimates up to 50%. Even using USPSTF’s more conservative 11%–19%, considered alongside localized survival above 99% and a 15%–20% relative reduction in breast-cancer mortality, the source argues that the balance remains favorable for most people. Avoid both extremes: abandoning screening through fear, or adding excessive screening through reassurance.
Putting the two sets of numbers together
The new JNCI 2026 analysis suggests overdiagnosis may be <5%. USPSTF’s own 2024 review reports around 11%–19% in the most rigorous trials; its models estimate about 14 overdiagnosed cancers per 1,000 women screened every two years from 40–74. Even the higher estimate is far below “30%–50%.” The lower estimate supports a more favorable balance for screening. Their difference illustrates why a personal risk-and-preference discussion is more useful than a slogan.

Borobudur, Central Java, photographed in Indonesia; unrelated to screening evidence.
IV. Risks and benefits: laying out both sides
The established benefits and meaningful costs of mammography can be listed separately.
Established benefits
Most meta-analyses estimate a 15%–20% reduction in relative breast-cancer mortality risk. The absolute reduction is modest, but for an individual, earlier detection often means less intensive treatment and a better prognosis. Together with localized survival above 99%, this supports screening’s public-health value.
Real costs
There are three. First, overdiagnosis exists whether estimated at 5% or 19%; some women receive avoidable treatment for lesions that would not have threatened life. Second, false positives are more common: lifetime biennial screening is estimated to produce about 1,376 false-positive results per 1,000 women, with repeat imaging, needle biopsies, and anxiety. Third, reduced effectiveness in some groups matters: dense breasts reduce mammographic sensitivity, are themselves an independent risk factor, and mean a negative result does not guarantee absence of disease. US reporting requirements include breast density.
The often-overlooked equity issue
Screening does not have the same balance for everyone. US Black women have about 40% higher breast-cancer mortality risk than White women, partly reflecting delays and differences in quality of life and treatment. Potential benefits may be greater, while information gaps also make participation less likely. Age 75 and above is another uncertain area: evidence is insufficient, so decisions usually account for comorbidity and life expectancy.
Competing schedules: annually or biennially, starting at 40 or 50?
For average-risk women, USPSTF 2024 recommends every two years at 40–74. The American Cancer Society (ACS) recommends annual screening from 45, then biennial screening after 55. ACOG offers annual or biennial screening from 40. These differences represent different weightings of false positives/overdiagnosis against the opportunity to detect rapidly growing tumors sooner.
The earlier start particularly affects women aged 40–49, whose incidence rose most clearly in the preceding decade and who face considerable uncertainty. Starting at 40 every two years is USPSTF’s baseline. With dense breasts, family history, or African ancestry, discussing frequency and supplemental testing is especially important. This decade is an opportunity to use risk stratification.

Prambanan, Central Java, photographed in Indonesia; unrelated to screening evidence.
V. Clinical implications: from “Should I screen?” to “How should I be screened?”
The practical questions are which risk group you belong to and how screening should be arranged.
- Stratify risk first. For average risk, USPSTF’s mammography every two years at 40–74 provides a baseline, reflecting the earlier start introduced in 2024. High-risk people—strong hereditary predisposition, previous atypical hyperplasia/lobular carcinoma in situ, chest radiotherapy, or BRCA and similar variants—are commonly advised annual mammography from around 30 and annual MRI from 25–35. Their screening framework differs from average-risk care.
- Know your density and risk. Mammogram reports classify density using BI-RADS A–D. Dense categories C/D reduce sensitivity. Discuss supplemental ultrasound or MRI rather than assuming one image provides complete reassurance. Family history or African ancestry supports early formal risk assessment.
- Distinguish breast awareness from screening. Self-palpation cannot replace mammography, but knowing what is normal and promptly seeking care for a new lump, dimpling, discharge, or skin change remains important. Screening looks for asymptomatic early disease; awareness detects an existing change. They complement each other.
- If using or considering menopausal hormone therapy (MHT), breast screening is part of follow-up. This is separate from deciding whether to use MHT. Do not avoid needed screening through fear of cancer, or treat completed screening as permission to relax assessment of MHT indications, duration, and monitoring. Bring both sets of information to your clinician.
- Reject both extremes. “Overdiagnosis scares me, so I will not screen” magnifies a potential cost into abandonment of benefit. “More frequent screening is always safer” creates more false positives and unnecessary invasive tests. Appropriate intensity based on risk is the goal.
- Bring questions. What is my risk category? At what age and interval should I screen? Does density warrant supplemental testing? If DCIS or a suspicious nodule is found, what follows? Written questions help obtain an individualized plan.
- A recall does not mean cancer is confirmed. Suspicious densities or calcifications may need ultrasound, additional/magnified mammographic views, or needle biopsy. Most ultimately prove benign. A recall means “clarify the finding,” not a final verdict.
- At 40–49, consider more than a birthday. This decade particularly needs individualized discussion after the starting age moved to 40. Higher-risk people with dense breasts, family history, or African ancestry may need earlier assessment and discussion of ultrasound/MRI. With lower risk, agreeing on starting age and frequency is more useful than automatically choosing annual imaging from 40. Base the decision on risk rather than a round number.
An emerging direction, for awareness rather than as a current standard
Risk stratification is moving beyond age and family history toward polygenic risk scores (PRS) and individualized models incorporating density. These may eventually identify who needs earlier or more frequent screening. They are not currently standard grounds for screening decisions; commercial “genetic fortune-telling” should not drive care.
VI. A rapid literature review for clinicians
For clinician readers, the key evidence is grouped as new analysis, current guidance, and important numbers:
- Principal new analysis: Njor SH, Urth Pedersen C, Lynge E, Smith RA, Rebolj M. Breast cancer overdiagnosis in mammography trials—separating signal from noise: a meta-analysis. J Natl Cancer Inst. September 14, 2026. Reanalysis of 8 RCTs in a common framework using long-term Funen data; overdiagnosis <5%, substantially below earlier 30%–50% estimates. Key adjustments: lead time and screening of controls after trial exit.
- Current guidance: USPSTF. Screening for Breast Cancer. 2024. Biennial mammography at 40–74, grade B; insufficient evidence at ≥75; its review estimates overdiagnosis at 11%–19%, modeling about 14/1,000. ACS 2015 update: annual from 45, biennial after 55; ACOG: annual or biennial from 40.
- Key figures: localized five-year relative survival >99%; relative mortality reduction with screening about 15%–20%; lifetime biennial screening false positives about 1,376/1,000; breast-cancer mortality risk about 40% higher in Black women; DCIS treatment intensity remains debated.
- Historical background: Pink October / Octobre Rose began in 1985 through ACS and Imperial Chemical Industries. Alexandra Penney and Evelyn Lauder established the pink ribbon with SELF magazine in 1992; 2026 is the 33rd edition, reaching 70+ countries.

Jakarta cityscape, photographed in Indonesia; unrelated to screening evidence.
VII. Returning informed choice to each person
The new evidence from 2026 points toward reassurance: cancers found through screening that would never need treatment may be much less common than often claimed, while early diagnosis and treatment can bring survival above 99%. Reassurance does not remove the need for judgment. Overdiagnosis may be smaller but remains real; false positives are more common; density, race, and age change the balance.
Pink October should return informed choice to people: knowing screening exists, what it can detect, and its limits. Whether deciding for yourself or advising as a clinician, remember three principles. Screening is worthwhile when tailored to risk. New research reduces estimated overdiagnosis without eliminating it: fear should not lead to abandonment, nor reassurance to excess. The final decision belongs in a conversation about your own risk, density, and preferences, rather than a slogan.
October’s lights will dim, but the questions should remain: when should I begin, which test should I have, and what happens after a finding? Bring those three questions to your doctor. The campaign’s most valuable result would be greater clarity and confidence about your own care, rather than illuminated landmarks alone.
Disclaimer:
This educational article draws on public literature and guidelines available through October 2026 and is not individualized medical advice. A qualified clinician should determine starting age, frequency, and supplemental ultrasound/MRI with you, using personal risk, density, family history, and local guidance. The cited research includes observational work and reanalysis; conclusions need validation through larger samples and longer follow-up.
Main information sources: Njor SH et al., J Natl Cancer Inst, September 14, 2026, mammography-trial overdiagnosis meta-reanalysis; USPSTF breast-screening recommendation (2024); ACS / ACOG / ACR guidance; reports of global landmarks illuminated pink on October 1, 2026, including the Eiffel Tower; public Octobre Rose 2026 schedules (33rd edition, 70+ countries); Hard Rock’s 27th PINKTOBER press release (launched September 28, 2026); Chiquita × ACS pink-label 2026 campaign information.
Read the source material
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


